Log in

NYSE:ABTAbbott Laboratories Stock Price, Forecast & News

$92.23
+0.59 (+0.64 %)
(As of 07/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$91.93
Now: $92.23
$93.06
50-Day Range
$87.30
MA: $90.59
$94.92
52-Week Range
$61.61
Now: $92.23
$100.00
Volume3.85 million shs
Average Volume6.27 million shs
Market Capitalization$163.14 billion
P/E Ratio46.35
Dividend Yield1.57%
Beta0.97
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides glucose and blood glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Read More
Abbott Laboratories logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.7Dividend Strength: 4.2Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.28 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
CIK1800
Phone224-667-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.90 billion
Cash Flow$5.02 per share
Book Value$17.70 per share

Profitability

Net Income$3.69 billion

Miscellaneous

Employees107,000
Outstanding Shares1,768,840,000
Market Cap$163.14 billion
Next Earnings Date7/16/2020 (Confirmed)
OptionableOptionable

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

How has Abbott Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ABT stock has increased by 18.1% and is now trading at $92.23. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Abbott Laboratories?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Abbott Laboratories.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, July 16th 2020. View our earnings forecast for Abbott Laboratories.

How can I listen to Abbott Laboratories' earnings call?

Abbott Laboratories will be holding an earnings conference call on Thursday, July 16th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) issued its quarterly earnings results on Thursday, April, 16th. The healthcare product maker reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.58 by $0.07. The healthcare product maker earned $7.73 billion during the quarter, compared to analysts' expectations of $7.47 billion. Abbott Laboratories had a net margin of 11.15% and a return on equity of 18.61%. The company's quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the company earned $0.63 EPS. View Abbott Laboratories' earnings history.

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Friday, June 12th. Investors of record on Wednesday, July 15th will be given a dividend of $0.36 per share on Monday, August 17th. This represents a $1.44 dividend on an annualized basis and a yield of 1.56%. The ex-dividend date is Tuesday, July 14th. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.08. View Abbott Laboratories' dividend history.

What price target have analysts set for ABT?

19 Wall Street analysts have issued 12-month price targets for Abbott Laboratories' stock. Their forecasts range from $84.00 to $109.00. On average, they anticipate Abbott Laboratories' share price to reach $100.27 in the next year. This suggests a possible upside of 8.7% from the stock's current price. View analysts' price targets for Abbott Laboratories.

Has Abbott Laboratories been receiving favorable news coverage?

News coverage about ABT stock has been trending negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Abbott Laboratories earned a news impact score of -2.5 on InfoTrie's scale. They also gave news headlines about the healthcare product maker a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the near term. View the latest news about Abbott Laboratories.

Who are some of Abbott Laboratories' key competitors?

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), AT&T (T), Walt Disney (DIS), NVIDIA (NVDA), Cisco Systems (CSCO), Pfizer (PFE), Home Depot (HD), Intel (INTC) and Verizon Communications (VZ).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the following people:
  • Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
  • Mr. Robert B. Ford, Pres & COO (Age 45)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by many different retail and institutional investors. Top institutional shareholders include Park National Corp OH (0.03%), First Financial Bank Trust Division (0.01%), Smithbridge Asset Management Inc. DE (0.00%), Boltwood Capital Management (0.00%), Thomasville National Bank (0.00%) and M&R Capital Management Inc. (0.00%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John F Ginascol, John G Stratton, John M Capek, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Philip P Boudreau, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View institutional ownership trends for Abbott Laboratories.

Which institutional investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, Thomasville National Bank, M&R Capital Management Inc., Nelson Van Denburg & Campbell Wealth Management Group LLC, Boltwood Capital Management, and Birch Capital Management LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Christopher J Scoggins, Jared Watkin, John F Ginascol, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Philip P Boudreau, Randel William Woodgrift, and Sally E Blount. View insider buying and selling activity for Abbott Laboratories.

Which institutional investors are buying Abbott Laboratories stock?

ABT stock was acquired by a variety of institutional investors in the last quarter, including First Financial Bank Trust Division, Ellenbecker Investment Group, Smithbridge Asset Management Inc. DE, Cox Capital Mgt LLC, and Red Spruce Capital LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift. View insider buying and selling activity for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $92.23.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $163.14 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is www.abbott.com.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.